Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q4 FY20 results · Jan–Mar 2020
Torrent Pharmaceuticals reported revenue from operations of ₹1,946.00 crore (up 4.8% from Q4 FY19) and net profit of ₹314.00 crore for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,946.00 | 1,856.00 | +4.8% | 1,966.00 | −1.0% |
| Other income | 15.00 | 17.00 | −11.8% | 53.00 | −71.7% |
| Total income | 1,961.00 | 1,873.00 | +4.7% | 2,019.00 | −2.9% |
| Profit before tax | 293.00 | (150.00) | Turned profit | 319.00 | −8.2% |
| Net profit for the period | 314.00 | (152.00) | Turned profit | 251.00 | +25.1% |
| EPS, basic (₹) | 18.56 | (8.95) | Turned profit | 14.77 | +25.7% |
| Net margin (%) | 16.1 | -8.2 | 12.8 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,491.00 | 1,357.00 | +9.9% | 1,471.00 | +1.4% |
| Other income | 21.00 | 227.00 | −90.7% | 62.00 | −66.1% |
| Total income | 1,512.00 | 1,584.00 | −4.5% | 1,533.00 | −1.4% |
| Profit before tax | 195.00 | 255.00 | −23.5% | 252.00 | −22.6% |
| Net profit for the period | 168.00 | 164.00 | +2.4% | 220.00 | −23.6% |
| EPS, basic (₹) | 9.91 | 9.73 | +1.8% | 12.97 | −23.6% |
| Net margin (%) | 11.3 | 12.1 | 15.0 |
Consolidated
- Filed with BSE
- 27 May 2020, 14:07 IST
- Board meeting
- 26 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 May 2020, 14:07 IST
- Board meeting
- 26 May 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE